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In a prospective cohort study 8466 women attending routine cervical cancer screening were recruited. Colposcopy was performed
on women with any degree of atypia on cytology and/or a positive high-risk human papillomavirus (HPV)-DNA test (HC2; Hybrid
Capture 2
r), and for a randomly selected sample of 3.4% women with negative findings on both. Quality control included reviews of
cytology, histology, colposcopy images and retesting of samples with polymerase chain reaction. Test diagnostic performances were
based on 7908 women who had complete baseline and follow-up results. Routine histology identified 86 women with high-grade
cervical intraepithelial neoplasia (CIN2þ), which was confirmed by review histology in only 46 cases. Sensitivity of routine cytology
for the detection of CIN2þ was 43.5%, with a specificity, positive predictive value (PPV), negative predictive value (NPV) of 98.0,
11.4 and 99.7%, respectively. Sensitivity of the HC2 test for the detection of CIN2þ was 97.8%, with a specificity, PPV and NPV, of
95.3, 10.9 and 100%, respectively. No high-grade neoplasia was detected in the randomly selected control group. A negative HPV-
test result, even in combination with a positive Papanicolaou (Pap) result, virtually excluded any risk of underlying high-grade disease,
but this was not the case for a negative Pap result. These data show that HPV testing is of value for the detection or exclusion of
prevalent CIN in a routine cervical cancer-screening setting and could be used for further risk classification of women for follow-up
management.
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Despite widespread cervical cancer-screening programmes, 30000
of the 190 million women living in Europe still die every year from
this disease (Ferlay et al, 1988). The overall decline in cervical
cancer incidence observed since the introduction of the Papani-
colaou (PAP) smear has levelled off and even started to increase in
countries such as England, Wales and Finland (Vizcaino et al,
2000), where organised screening programmes with extensive
quality control have been in place for many years.
In Germany, an opportunistic cervical cancer-screening
programme was established in 1971, which made free annual
cervical cancer screening available to all women 20 years of age or
older. The average annual participation rate in 1997 was roughly
50% (Kahl et al, 1999; Klug et al, 2000; Klug and Blettner, 2003).
When looked at over a 3-year period, which is the screening
interval used in many European countries, the population coverage
reaches 80% (Schenck and von Karsa, 2000) or higher in the 25–
50-year-old age group. Despite this considerable effort, Germany
has one of the highest cervical cancer incidence rates (13.28 per
100.000) and standardised mortality rates (4.4 per 100.000 for
1993) in Western Europe, which is higher than in neighbouring
countries with similar socio-economic structures such as France,
Italy and the Netherlands.
Infection with high-risk human papillomavirus (HR-HPV) is the
major risk factor for the development of cervical cancer (Bosch
et al, 1995; Walboomers et al, 1999) and it has been suggested that
testing for HR-HPV should be included in existing cervical cancer-
screening programmes (Vizcaino et al, 2000). Large-scale screen-
ing studies by Schiffman et al (2000), Clavel et al (2001) and
Schneider et al (1996, 2000) demonstrated that HPV testing is
more sensitive for the detection of high-grade cervical lesions than
cytology although the lower specificity of HPV testing made its use
in primary cervical cancer screening questionable. However, the
majority of these studies did not compare HPV testing to routine
cytology, but rather used a team of expert cytologists thereby not
allowing to draw conclusions about the performance of HPV
testing under routine screening conditions. In addition, these
studies included a high proportion of younger women aged 18
years and above, although it is known that young, sexually active
women have a high prevalence of both HR-HPV and high-grade
cervical intraepithelial neoplasia (CIN), the overwhelming majority
of which resolves spontaneously (Evander et al, 1995; Ho et al,
1995). It is possible that the higher sensitivity of HR-HPV testing
in these young populations in comparison with cytology may
partially be because of the identification of transient disease with a
high tendency for regression. To address this particular issue,
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yCuzick et al (1999) examined the performance of HPV testing in
women 35 years of age or older and again found that HR-HPV
testing had a higher sensitivity than cytology, but a lower
specificity and positive predictive value (PPV) leading to a higher
referral rate than cytology alone. Importantly, all of the former
studies are characterised by the lack of an HPV /Pap  control
group examined by colposcopy, thereby not allowing an accurate
estimate of the false-negative rate of the screening regimen
(Ratnam et al, 2000).
Our aim was to determine the value of HPV testing in the
routine primary cervical cancer-screening programme in Germany
for the detection of high-grade cervical cancer precursors
(XCIN2). To avoid confounding factors, we implemented different
levels of quality controls (see study protocol in Figure 1) to
evaluate the use of HPV testing. All the 8083 study participants
finally included were aged 30 years or older attending for routine
cancer screening and represented a random unselected population
that was highly representative of Western Germany as a whole.
All positive and 5% of the negative HC2 samples were retested
by a highly sensitive, broad-range, consensus-primer PCR with
direct sequencing to evaluate HC2 performance. Digital images of
the cervix were taken at the colposcopic examination and reviewed
by independent experts blinded to previous findings. Additional
expert reviews were performed on all histology samples and all
cytology samples with any degree of dyskaryosis, all cytology
samples from HR-HPVþ women and 5% of randomly selected
cyto-/HPV-cytology samples. Most importantly, a colposcopic
examination of a random sample of 250 women who were cytology
and HPV  was performed in order to estimate the bias that would
be introduced by disease missed in women who were falsely
negative on both tests (Ratnam et al, 2000). Cytology labs
undertaking the primary cytology were not informed about which
Pap smears were included in the trial and the samples were
therefore screened under routine conditions. The statistical
analysis of the raw data was performed by an independent group
(Erasmus University, Rotterdam) that was not involved in the
screening trial nor in the collection of the data.
MATERIALS AND METHODS
Study population
Between December 1998 and December 2000, 8466 women
attending routine cervical cancer screening were recruited from
28 urban, suburban or rural, office-based gynaecological practices
from Hannover and Tuebingen and the surrounding areas. Women
were eligible for inclusion if they were attending for routine annual
cervical cancer screening, were 30 years of age or older, had not
undergone a hysterectomy, had no history of atypical cytology,
CIN, or treatment for cervical disease in the preceding year and
were currently not pregnant.
Of the 8466 women enrolled in the study, 8101 women met the
inclusion criteria. Of the 4566 participants from Tu ¨bingen, 233
(5.1%) were excluded, leaving 4333. Of the 3900 women enrolled
from Hannover, 132 women (3.4%) were excluded leaving 3768.
Reasons for exclusion (365 women) were: 43 women with genital
warts; 13 women with a history of conisation or hysterectomy; 11
women who were pregnant; eight women with abnormal cytology
within 1 year of study entry; 167 women who were under the age of
30 years and 123 women who had not given written consent.
Written informed consent was obtained from the patients by the
participating gynaecologists. The study was approved by the local
ethics committees at the Universities of Hannover and Tuebingen.
Screening examinations
At the first gynaecological examination, the cervix was visualised
and a sample was taken for routine cervical cytology following the
procedures normally used in each gynaecological practice (most,
but not all, samples were taken with a cotton-tipped swab, rolled
onto a microscope slide and spray fixed). This practice of sample
taking is the standard recommended procedure in Germany (Link
M and Link H, 2001). A second sample was then obtained with a
cervical sample device (Digene Inc. Gaithersburg, MD, USA) and
suspended in 1ml of specimen transport medium (STM/ Digene
Inc, Gaithersburg, MD, USA) for HPV DNA testing. Women were
allocated to follow-up according to the protocol illustrated
(Figure 1).
Cytological diagnoses
All cervical smears were analysed at one of the cytology
laboratories normally used by each participating office-based
gynaecology practice and reported in accordance with the Second
Munich Cytological Classification (Table 1). The ‘Pap II w’
(W¼wiederholen¼repeat) is a widely used category although it
is not an official cytological classification. It is used by cytologists
to describe inadequate specimens, minimal changes and koilocytes
in the absence of further abnormalities or atypical squamous cells
of undetermined significance (ASCUS). In this study, smears were
considered positive if any degree of cytological abnormality was
observed (XPapIIw, Eborderline/ASCUS) in order to maximise
detection of disease. The cytology laboratories had not been
informed about the study and were therefore analysing the smears
under routine screening conditions. All glass slides and accom-
panying forms lacked information on the patient’s participation in
a trial to prevent bias in reading.
Cytology and
HPV testing
Cytology– 
 and  
HPV– 
Cytology+ 
 and/or  
HPV+ 
Biopsy and 
histology
Colposcopy Colposcopy
Routine 
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follow-up
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Treatment if  
 CIN2/3
95% Random 5%
+ +  –  – 
100%
Quality
control 
Cytology review
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with sequencing
Computer-assisted
 digital
imaging and review
Expert histology

Figure 1 Study Protocol.
Table 1 Correlation between second Munich classification and the
Bethesda system
Munich classification Bethesda correlate
PapI/II Normal/inflammatory
PapIII ASC-H and AGUS–cannot exclude
high-grade disease or cancer
PapIIId CIN1–2
PapIVa CIN3–carcinoma in situ
PapIVb Carcinoma in situ–microinvasive carcinoma
PapV Microinvasive carcinoma–invasive carcinoma
Unofficial classification Bethesda correlate
PapIIw Includes inadequate and ASC-US
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Samples for HPV testing were stored at 41C for a maximum
of 4 weeks prior to testing. All primary HPV testing was
undertaken using the Hybrid Capture 2 test (HC2/Digene Inc,
Gaithersburg, MD, USA) at the clinical diagnostic laboratory
of the Medizinische Hochschule Hannover or at the Department
of Experimental Virology at the University of Tuebingen. All
samples were analysed for the presence of 13 HR-HPV types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) following
the manufacturer’s instructions. Therefore, a positive HPV
result refers to a patient who is positive for one or more of
the 13 HR-HPV types included in the high-risk probe mix.
Infection with low-risk HPV types was not evaluated. Samples
were considered positive if they attained or exceeded the
FDA-approved threshold of 1.0pg HPV DNAml
 1, which corre-
sponds to 1.0 relative light units (RLU). All samples with RLU
values in the range of 0.7–2.0RLU were retested in duplicate,
although subsequent statistical analysis was based only on the
primary measurement.
HPV testing by PCR
DNA extraction, sample preparation and sample analysis
procedures were carried out in separate rooms. All samples were
tested for DNA integrity by PCR using primers for the human b-
globin gene. Three different primer combinations were used
(PPF1/PPR2, PPF1/CP5, CP4/CP5) producing amplicons
ranging in size from 220 to 450bp, all located in the highly
conserved helicase region of the E1 gene. The sensitivity of this
PCR system for different HPV types was established by testing
serial dilutions of HPV plasmids for the following types:
HPV1–8, 10–19, 21–26, 30–38, 40, 45–47 and 60, both in the
presence and absence of human placenta DNA (1mg). Primers
PPF1/PPR2, which are not degenerate, reach the highest sensiti-
vity of 10 genome copies per sample and result in a single
220bp amplification product when applied to DNA extracted
from clinical samples. PPF1/CP5 and CP4/CP5 have a detection
limit of 100 copies, which is by far sufficient for the testing of
clinical samples of the cervix. Primers PPF1/CP5, where the
downstream primer is degenerate in three positions, detect at least
64 different HPV types and produce a 280bp amplicon, while
primers CP4/CP5 with five degenerate nucleotide positions
generate a fragment of 450bp that has been described elsewhere
(Tieben et al, 1994). The nucleotide sequence of the primers is as
follows:
PPF1 50-(nt 2082)-AAC-AAT-GTG-TAG-ACA-TTA-TAA-ACG-
AGC-(nt 2108)-30
PPR2 50-(nt2336)-ATT-AAA-CTC-ATT-CCA-AAA-TAT-GA-
(nt2314)-30
CP4 50-(nt1942)-ATG-GTA-CAR-TGG-GCA-TWT-GA-
(nt1961)-30
CP5 50-(nt 2400)-GAG-GYT-GCA-ACC-AAA-AMT-GRC-T-
(nt 2378)-30
Numbers are according to the sequence of HPV16W12E
(Genbank IDNr. AF125673).
Direct automated sequencing of the PCR products was carried
out using the Big Dye Terminator Cycle Sequencing Ready
Reaction Kit (PE Biosystems, Foster City, CA, USA). Sequencing
was performed in 47cm capillaries with the use of an ABI 310
sequencer (PE Biosystems). Sequences with o5% unidentifiable
bases were processed and compared with those of known HPV
types available through the GenBank database (NCBI, Bethesda,
MD, USA) using the Blast program. A nucleotide sequence was
regarded as a distinct HPV type if it demonstrated o90%
homology with a known type.
Colposcopic referral
Women were called for colposcopy at either of the two university
gynaecology clinics if they demonstrated any degree of cytological
abnormality (XPapIIw; Eborderline/ASCUS) and/or if they were
positive for HR-HPV. In addition, a random sample of 5% of
women who were negative on both screening tests were invited to
attend for colposcopy in order to assess the prevalence of high-
grade disease in this population. The median recall interval (time
from initial screening examination to attendance for colposcopy)
was 79 days with a range from 12 to 128 days. At colposcopy,
punch biopsy specimens were taken from any regions suspicious
for CIN and final diagnoses were based on histological results
expressed using the Bethesda terminology. Cases were defined as
women with high-grade cervical disease (XCIN2) using expert
histology based on the primary histological result and two
independent, blinded reviews.
Quality control procedures
An extensive series of quality control procedures was implemented
(Figure 1). All abnormal cytology, all cytology from women
positive for HR-HPV and 5% of normal cytology were mixed 1:1
with normal Pap smears and reviewed by one of the two
independent expert cytopathologists (Professor Dr med. M
Hilgarth, Professor Dr med. N Freudenberg, Universita ¨tsfrauen-
klinik Freiburg). All statistical analyses were based on primary
cytology and review cytological diagnoses were used for quality
control purposes only. All histological specimens were
reviewed by an independent expert histopathologist (Professor
Dr Hans-E Stegner, University of Hamburg/retired) and
specimens showing significant disagreement between primary
and review histology were referred to a third histopathologist (Dr
C Bergeron, Laboratoire Pasteur Cerba, France). All statistical
analyses were based on combined expert histology achieved in the
following way:
(1) All histology diagnoses were classified into cases (XCIN2)
and noncases (oCIN2, VIN, VaIN).
(2) If routine histology and the review differed between those
categories, a third histology diagnosis (second review) was
included. A patient was then defined as case if the quotient of
case/noncase was 2.0 and as noncase if the quotient was 0.5.
All independent experts were completely blinded to previous
findings. Colposcopy was quality controlled using a computer-
assisted digital imaging system (DenVu, Tucson, AZ, USA) initially
developed for the ASCUS-LSIL Triage Study (ALTS) conducted by
the NCI (Solomon et al, 2001). Finally, HPV-DNA testing was
quality controlled by the inclusion of three known positive samples
and three known negative samples that are included with the HC2
kit; the modification of HC2 analysis software to require the
inclusion of four blind samples with each test run, which must give
results within a predetermined range for the run to be valid (blind
control samples provided by Digene Inc). In addition, 7.5% of all
HC2 samples were exchanged between Hannover and Tuebingen
for retesting. Both labs were blinded to previous results. In
addition, all samples with either a positive test result from cytology
or HC2 or from both and 5% of the negative samples were retested
by PCR and positives were directly sequenced to confirm their
status.
Data analysis
All statistical analyses were undertaken by an independent group
that did not participate in the screening trial or in the collection of
the data. All test results were stored in a Microsoft Access database
in Hannover and Tuebingen and later combined into one file
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were categorised into positive (XPapIIw; Eborderline/ASCUS) or
negative results. An HPV-HC2 result was considered positive when
it attained or exceeded the FDA-approved threshold of 1.0pg HPV
DNAml
 1, which corresponds to 1.0 RLU. The cytology and HPV-
HC2 test reviews were not used for the calculation of the test
properties. Histology results were considered positive for CIN2
and higher. Vaginal intraepithelial neoplasia (VaIN) and vulvar
intraepithelial neoplasia (VIN) were not considered as positive
results for this analysis. The test sensitivity, specificity, PPV and
negative predictive value (NPV) were calculated by contingency
table analysis with 95% confidence intervals assessed using logistic
regression, using a weighting factor. The women were divided into
four groups according to their cytology and HPV-test results: both
cytology and HPV ; cytologyþ, HPV ; cytology negative,
HPVþ; both cytology and HPVþ. In women with both cytology
and HPV  test results, only a small percentage has had a
colposcopic examination and histology results were available. The
assumption was made that this selected group of women who
underwent colposcopy are representative of all the women in the
double-negative group. By multiplying the cases (women with
‘final histology’ XCIN2) of the double-negative group by the
weight factor (total number of double-negative women divided by
the number of women of this group that underwent colposcopy)
the total number of cases could be estimated as if every woman
would have had histology. The confidence intervals were calculated
with logistic regression taking into account this weight factor. In
some subgroups, test properties were 100%. In these instances, the
log likelihood for the underlimit of the confidence intervals was
calculated by the following formula 1 e
ln(0.05)/n, with n being the
number of observations in women who had a colposcopy result.
RESULTS
The mean age of the 8101 women included in the study was 42. 7
years, with 94.6% of the women between 30 and 60 years of age. Of
the 8101 women included in the study, 18 women did not have a
cytology result, leaving 8083 women with both a cytology result
and an HPV-HC2 result at baseline. Of the 8083 women with
complete baseline results, 251 women (3.1%) had cytological
abnormalitiesXPapIIw (Eborderline/ASCUS), which included
one woman with PapIVb (XCIN3), eight women with PapIVa
(CIN3), 61 women with PapIIID (CIN1–CIN2), 14 women with
PapIII (ASC-H/AGUS) and 167 women with PapIIw (Eborderline/
ASCUS). In all, 521 (6.4%) women were positive for HR-HPV
(Table 2). All 711 women with a positive result for at least one of
the tests were invited for colposcopy, but 175 of them refused
examination. They were excluded from further analyses, leaving
7908 women meeting the inclusion criteria and having results for
both tests at baseline and follow-up with 3683 from Hannover and
4225 from Tuebingen.
In all, 5% of the double-negative women were randomly selected
and invited for colposcopy, 250 women (3.4%) responded to this
invitation. The results for these women were considered repre-
sentative for all double-negative women. Based on extrapolation of
the primary histology results of the double-negative control group
(five cases of CIN2þ in 250 women), we calculated that 247 out of
the total cohort of 7908 women would have had the routine
diagnosis of high-grade cervical disease (XCIN2). However,
independent blinded reviews by two pathologists of all histology
slides stated that none of these controls showed any degree of
neoplasia. Further, review of the digital colposcopic images
confirmed the absence of disease in this group. There was
complete agreement between primary and review colposcopy in
terms of normal colposcopy results for all those women with
normal Pap smears and negative HPV tests who had no cervical
biopsy.
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536 women attending colposcopy, from which only 46 cases were
confirmed on expert review histology. Of the 46 women with high-
grade cervical disease on expert histology, 20 would have been
detected on the basis of cytology alone (Figure 2) using the lowest
possible threshold (XPap IIw) for referral to colposcopy, for a
sensitivity, specificity, PPV and NPV of 43.5, 98.0, 11.4 and 99.7%,
respectively (Table 3).
Human papillomavirus-positive status was strongly associated
with the detection of cervical disease. In all, 45 of the 46 cases were
positive for HPV (Figure 3) using the 1.0pg HPV-DNAml
 1
threshold, giving a sensitivity and specificity of 97.8 and 95.3%,
respectively. The positive and negative predictive values of HPV
testing were 10.9 and 100%, respectively. Combining cytology with
HPV testing increased sensitivity to 100%, with a specificity, PPV
and NPV for the combined test protocol of 93.8, 8.6 and 100%,
respectively (Table 3). While this approach offered the best in
terms of safety, it led to the highest number of follow-up
examinations (6.8%).
Of the 37 women with CIN3 or invasive cervical carcinoma,
20 had completely normal Pap smears. Of the remaining 17
women, two had smears classified as PapIIw (ASUCS,
borderline), one had PapIII (ASC-H/AGUS), nine had PapIIID
(CIN1-CIN2), four had PapIva (CIN3) and one had PapIvb
PapI/II
n = 7832
96.9%
HPV+
n = 460
5.9%
HPV_ HPV_ HPV_ HPV_ HPV_
n = 7372
94.1%
HPV+
n = 18
10.8%
n = 149
89.2%
HPV+
n = 3
21.4%
n =11
78.6%
HPV+
n = 31
50.8%
n = 30
49.2%
HPV+
n = 9
100%
n = 0
0%
26 cases 0 cases
PapIIw
n = 167
2.1%
0 cases 3 cases
PapIII
n = 14
0.2%
2 cases 0 cases
PapIIId
n = 61
0.8%
9 cases 1 case
PapIV+V
n = 9
0.1%
5 cases 0 cases
Figure 2 Patients grouped by cytology, HPV-test results and their confirmed histology results.
Table 3 Test performance of HC2 and cytology at different thresholds for detection of histologically confirmed CIN2+ or CIN3+
Sensitivity % Specificity % PPV % NPV %
For CIN2+ 95% CI 95% CI 95% CI 95% CI Referred
PapIIw+ 43.5% 30.0–58.0 98.0% 96.7–98.8 11.4% 7.5–16.9 99.7% 98.7–99.9 2.2%
PapIII+ 37.0% 24.4–51.6 99.4% 98.5–99.8 27.0% 17.5–39.2 99.6% 98.8–99.9 0.8%
HPV 97.8% 86.3–99.7 95.3% 93.5–96.6 10.9% 8.2–14.2 100.0% 55.3–100 5.2%
HPV/PapIIw+ 100.0% 93.7–100 93.8% 91.8–95.3 8.6% 6.5–11.3 100.0% 98.8–100 6.8%
For CIN3+
PapIIw+ 46% 30.8–61.9 98.0% 96.7–98.8 9.7% 6.1–15 99.7% 98.8–99.9 2.2%
PapIII+ 40.5% 26.1–56.8 99.4% 98.5–99.8 23.8% 14.9–35.8 99.7% 98.9–99.9 0.8%
HPV 97.3% 83.2–99.6 95.2% 93.4–96.5 8.7% 6.3–11.8 100.0% 55.3–100 5.2%
HPV/PapIII+ 100.0% 93.7–100 94.9% 93.1–96.2 8.4% 6.2–11.4 100.0% 99.1–100 5.6%
Women included
in analysis
N = 7908
Pap = neg
HPV = pos
N = 360
Pap = pos
HPV = neg
N = 122
Pap = pos
HPV = pos
N = 54
Pap = neg
HPV = neg
N = 7372
Colposcopy
N = 360
biopsy
N = 247
Colposcopy
N = 122
biopsy
N = 69
Colposcopy
N = 54
biopsy
N = 44
Colposcopy
N = 250
biopsy
N = 69
Cases CIN2+
N = 26
Cases CIN2+
N = 1
Cases CIN2+
N = 19
Cases CIN2+
N = 0
Figure 3 Patients divided into four groups according to their cytology and HPV test, follow-up management and confirmed histology results.
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smear classified as PapIII (ASC-H/AGUS). Human papillomavirus
testing of these 37 women identified 36 women who were positive
for HR-HPV, with the one case missed having a borderline
negative result (0.83) that stayed negative after three-fold repeated
retesting (average¼0.993) with HC2 and was subsequently found
to be positive for HPV 18 upon testing by PCR and sequence
analysis. Of the 17 women who would have been detected by
cytology, 16 were also positive for HR-HPV with the one
discrepant case being the woman with CIN3 who was positive
for HPV 18 on PCR/sequencing analysis. Using a case definition of
CIN3þ, the sensitivity, specificity, PPV and NPV of cytology were
46, 98.0, 9.7 and 99.7%, respectively, while the corresponding
parameters for HPV testing were 97.3, 95.2, 8.7 and 100.0%
(Table 3).
The sensitivity of cytology given above is based upon a Pap-
smear result of XPapIIw (Eborderline/ASCUS), which is lower
than the usual threshold used in Germany. Using the usual
threshold of XPapIII (XASC-H/AGUS), as the basis for referral to
colposcopy, the sensitivity of cytology would have decreased
to 37.0%, while the positive predictive value would have increased
to 27.0% (Table 3). It has to be noted that the current analyses on
test performances are based on the 7908 women with complete
baseline and follow-up results. If we would include the women with
a positive test for at least one of the tests at baseline that refused
colposcopy (and were therefore excluded from the primary
analysis) under the assumption that no cases would have been
detected in these women, this leads to similar results as presented.
Assuming, however, the other extreme that all 175 women who
refused colposcopy would have been cases leads to a considerable
lower sensitivity of the HPV test of 68.8%, while the sensitivity of
cytology (43.0%) does not change significantly. Since the
distribution of cytology or HPV positivity among the 175 women
who refused colposcopy did not differ from the 711 participants
who were examined, it is not likely that the exclusion of
noncompliant women had any significant effect on the analysis.
A total of 925 of the routine cytology samples were reviewed by
an independent expert, who noted at least minor deficiencies of
sample fixation, staining or mounting in 19.8% of all slides. The
primary cytology result and the review result were in agreement
for 719 out of 925 (77.7%) Pap smears. In total, 87 out of 206 (42%)
of the different cases involved a discrepancy of two or more grades
(kappa value¼0.25). Using review cytology with PapIIw (Ebor-
derline/ASCUS) or higher as the basis for referral to colposcopy
would have missed two cases identified on primary cytology, and
would have identified an additional five cases.
QA testing of HC2-positive samples demonstrated a very high
correlation between the two laboratories involved in this study. On
the whole, 300 samples from the clinical laboratory at the
Medizinische Hochschule Hannover were retested at the Depart-
ment of Virology University of Tuebingen, and 300 samples from
Tuebingen were retested in Hannover. In all, 96.6% of the samples
yielded the same result on repeat HC2 testing for a kappa value of
0.75 (95% CI: 0.64–0.85).
DISCUSSION
This trial is one of the first large-scale evaluations of HPV testing
within an established nationwide cervical cancer-screening pro-
gramme under routine screening conditions. Owing to the
nonselected study population and the inclusion of rural and urban
regions from both Northern and Southern Germany, the data are
highly representative of Western Germany as a whole.
Ideally, routine screening for cervical cancer based on Pap
smears should detect all high-grade neoplasia in a given
population, while testing for HPV, as the causative agent of
cervical cancer, should identify all individuals either having
prevalent cervical neoplasia or of being at risk for developing
incident cancer within the next decade. Combining both methods
should enable a reliable risk stratification of the screened
population and allow for the development of a risk-adapted
screening programme with increased intervals for women at
greatly reduced risk. Important aspects of this hypothesis are
indeed supported by the results of this study. As expected, the
group of Cytoþ/HPVþ women contained the highest proportion
of high-grade cervical neoplasia (19 out of 54), while no cases were
found on colposcopic examination of 250 randomly selected
women who were negative on both cytology and HPV testing. It is
a limitation of this study that we were not able to examine 10% of
double negatives as claimed by others to be adequate to assess
verification bias, although the results from our colposcopy review
process and preliminary follow-up data make it unlikely that cases
were missed. This verifies the widespread belief that Cyto /HPV 
women are at significantly reduced risk of having high-grade CIN
or cancer at the time they are tested. In addition, they should be
protected for an extended period against the development of
cervical cancer as suggested by other investigators (Rozendaal et al,
2000; Clavel et al, 2001). However, sufficient data are not yet
available to define the length of the protective effect in Cyto /
HPV  women. Once defined, this could have an enormous impact
on the frequency of testing and the cost efficiency of a screening
programme. It should be noted, however, that lack of compliance
for follow-up examinations as observed in this study among 20%
of women being positive by either test compromises the success of
any screening algorithm, independent of individual test perfor-
mances.
The largest group of 26 cases was found among 460 women with
normal cytology but positive HPV-test results, whereas only a
single case was detected among 190 participants with abnormal
cytology but negative HPV results. This high number of false-
negative Pap-smear results could be because of the fact that
routine standard Pap-smear procedures have been performed at
office-based gynaecologists and cytology slides were read in
private laboratories as part of the German cervical cancer-
screening programme, which has considerably reduced the
reimbursement rates for a Pap smear during the last decades.
Other screening trials using a defined team of specialists for
collecting samples and reading Pap smears indeed found a higher
sensitivity for cytology for high-grade cervical neoplasia (Schiff-
man et al, 2000; Clavel et al, 2001) than observed here or in recent
studies that evaluated routine Pap smears (Ratnam et al, 2000;
Schneider et al, 2000). In addition, the standard recommended
practice in Germany of taking samples with cotton-tipped swabs
(Link M and Link H, 2001), which has been demonstrated to
harvest fewer cells than other collection devices may also be
responsible for these false-negative results (Martin-Hirsch et al,
1999) and may have biased the study results in favour of HPV
testing.
A major factor contributing to the high number of ‘false-
positive’ Pap smears was the cytological diagnosis ‘Pap IIw’ that
denotes inflammation, minimal cytological changes or ASCUS,
which is not part of the official Munich cytology classification
system (Table 1). This diagnosis was the most frequent abnormal
result with a total of 167 women (2.1%) receiving it. Only three
cases of CIN2þ were found in women with PapIIw (Eborderline/
ASCUS) results and all were associated with a positive HC2 result,
while no case was detected among 149 (89.2%) women with PapIIw
(Eborderline/ASCUS) and a negative HPV test result (Figure 2).
In contrast, only one of 41 HPV  Pap smears either classified as
PapIII (ASC-H) or as PapIIID (CIN 1 or CIN 2) was associated with
high-grade disease. HPV testing proved to be highly efficient in
triaging women with abnormal Pap findings because 19 out of 20
cases of underlying CIN2þ were HPVþ, while 190 out of 251
patients with negative HC2 results could have been returned to the
routine screening pool.
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Pap smear seen in our trial and a former study from Germany
(Schneider et al, 2000), it is questionable if a risk-adapted
screening programme would benefit from the inclusion of
conventional cytology. Whereas a negative HPV test result, even
in combination with a positive Pap result, virtually excluded any
risk of the underlying disease, a single negative Pap smear missed
more than 50% of cases. Owing to this, cervical cancer screening in
Germany relies on annual screening to achieve a sufficient
sensitivity by repeated rounds of testing. This will, however, only
work if the compliance among women participating in screening
stays constant from year to year. In contrast, a screening protocol
based on HPV testing alone would have detected 45 out of 46 cases
in this study with a colposcopy referral rate of 11.6 (521/45)
patients per case detected, while cytology detected only 20 out of
46 cases with a referral rate to colposcopy of 12.6 (251/20) patients
per case detected. It has to be noted, however, that any effort to
intensify cervical cancer screening, which increases the number of
test-positive women, bears in conjunction with the low reprodu-
cibility of cervical cytology and histology observed in this study a
potential risk of patient overexamination.
Although the high sensitivity and the high negative predictive
value are obvious advantages of the HPV test, its use as a primary
screening tool is hampered by its low specificity and the risk of
possible overtreatment of HPV-test-positive women. One con-
tributing factor to the low specificity is the crossreactivity of the
HC2 high-risk hybridisation probe with low-risk HPV types or
HPV types of undetermined risk as discussed in earlier studies
(Peyton et al, 1998; Vernon et al, 2000; Solomon et al, 2001). Here
we found a substantial degree of crossreactivity (6.4%) between the
HC2 high-risk probe and HPV types not included in the probe
cocktail by retesting all HC2þ samples with PCR followed by
direct sequencing and by additional testing with the PGMY09/11-
PCR system coupled to a reverse hybridisation line-blot assay
(Kornegay et al, 2001) to be able to detect multiple infections. If
the problem of crossreactivity theoretically could be eliminated,
this would have increased the specificity of the HC2 test up to
97.6% without losing sensitivity (data not shown). In addition, we
found a significant false-positive rate of 3.6% and a false-negative
rate of 6.1% of all samples as defined by different results from HC2
vs a highly sensitive PCR/sequencing assay. Clearly, attempts to
reduce or eliminate crossreactions and false positives/negatives
would be a worthwhile strategy to achieve a better specificity of
HPV testing, without affecting its sensitivity.
The use of an improved highly specific HPV test for primary
cervical cancer screening in a generally low-risk population (6.4%
HPV prevalence), as in Germany, holds great promise. Given the
low prevalence of HPV infection in the female population aged 30
or above, combined with the high sensitivity of the HC2 test,
E94% of women could have been returned safely to routine
screening, while detecting virtually all of clinically relevant
diseases. Theoretically, in a country like Germany, a significant
benefit could be expected even from a twice in a lifetime HPV test.
The timing of the first lifetime test should be sufficiently late in
life, such that most HPV exposure has already occurred, but, on
the other hand, sufficiently early to keep the risk of missing
prevalent invasive cervical cancer to a minimum. It is expected
that the cost efficiency of HPV testing will be poor in age groups
under 30 years of age, because transient HPV infections are
common (Evander et al, 1995) and cervical cancer is rare. The
second lifetime test should be used to define type-specific
persistence of an infection and include viral load analysis
(van Duin et al, 2002), which is not yet available as a commercial
routine test. Based on these results, suitable surveillance
mechanisms, like colposcopy/biopsy, will have to be applied to
follow-up patients with a substantially increased risk for cervical
cancer. Further, if the preliminary results regarding the negative
predictive value of HPV testing are confirmed in large-population-
based studies over the longer term (45 years), those women with
low-risk sexual behaviour who are negative both on cytology
and on HPV test could be grouped safely on a recall interval
of 3–5 years or more, which would generate savings that could be
applied to a better surveillance for those women who are at
increased risk.
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